• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Consumer Cyclical·301009.SZ
Share

Hangzhou Coco Healthcare Products Co.,Ltd. Stocks

CN¥ 8.28Last Updated 14.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 327.13M

CN¥ 8.28
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hangzhou Coco Healthcare Products Co.,Ltd. is a Chinese enterprise dedicated to the innovation, manufacturing, and distribution of products across three main categories: baby care, adult incontinence, and pet hygiene. Its extensive portfolio of adult incontinence solutions features items such as adult diapers, pull-up pants, nursing pads, maternity towels, and menstrual pants, alongside a variety of general absorbent towels and specialized absorbent pads for men. Established in 2001, the company was initially known as Hangzhou Qiaozi Paper Industry Co.,Ltd. before adopting its current name, Hangzhou Coco Healthcare Products Co.,Ltd., in December 2011. Its operations are based in Hangzhou, China.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 10:25

Morning Roundup: IBM's Worst Day, Stripe Sets Its Sights on PayPal, and an OpenAI Gadget

15.07.2026 09:30

Goldman Sachs: The AI boom has reached the same scale as the dot-com boom, but is following a different trajectory

15.07.2026 08:30

Nuclear fusion projects have raised a record $4.5 billion. Is a new boom underway?

15.07.2026 07:30

Chinese AI developer DeepSeek has begun preparations for an IPO next year — Bloomberg

15.07.2026 03:24

Lucid's stock plummeted following news of a possible bankruptcy. At one point, it was down 57%.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026